Litigation Details for Vytacera Bio, LLC v. CytomX Therapeutics, Inc. (D. Del. 2020)
✉ Email this page to a colleague
Vytacera Bio, LLC v. CytomX Therapeutics, Inc. (D. Del. 2020)
Docket | ⤷ Try a Trial | Date Filed | 2020-03-03 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:1 Patent Infringement | Assigned To | Leonard Philip Stark |
Jury Demand | Plaintiff | Referred To | Christopher J. Burke |
Patents | 9,775,913 | ||
Link to Docket | External link to docket |
Biologic Drugs cited in Vytacera Bio, LLC v. CytomX Therapeutics, Inc.
Details for Vytacera Bio, LLC v. CytomX Therapeutics, Inc. (D. Del. 2020)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2021-10-07 | 130 | Report and Recommendations | two patents-in-suit: United States Patent Nos. 8,809,504 (the “'504 patent”) and 9,775,913 (the…the “'913 patent” and collectively with the '504 patent, the “patents-in-suit”). (See D.I…x27;504 patent, and claims 1 and 22 of the '913 patent. Claim 1 of the '504 patent is representative…it owns the rights to the '504 patent and the '913 patent, (id. at ¶¶ 25, 32). CytomX is a…hereinafter, “'504 patent”) Abstract; id., ex. 2 (hereinafter, “'913 patent”), Abstract) The & | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |